Original Article

You have full text access to this OnlineOpen article

Nonsteroidal anti-inflammatory drugs†

Effects on mortality after colorectal cancer diagnosis

  1. Jason A. Zell DO, MPH1,2,‡,*,
  2. Argyrios Ziogas PhD1,
  3. Leslie Bernstein PhD3,
  4. Christina A. Clarke PhD4,
  5. Dennis Deapen DrPH5,
  6. Joan A. Largent PhD1,
  7. Susan L. Neuhausen PhD1,
  8. Daniel O. Stram PhD5,
  9. Giske Ursin MD, PhD5,
  10. Hoda Anton-Culver PhD1

Article first published online: 13 OCT 2009

DOI: 10.1002/cncr.24705

Issue

Cancer

Cancer

Volume 115, Issue 24, pages 5662–5671, 15 December 2009

Additional Information

How to Cite

Zell, J. A., Ziogas, A., Bernstein, L., Clarke, C. A., Deapen, D., Largent, J. A., Neuhausen, S. L., Stram, D. O., Ursin, G. and Anton-Culver, H. (2009), Nonsteroidal anti-inflammatory drugs. Cancer, 115: 5662–5671. doi: 10.1002/cncr.24705

Author Information

  1. 1

    Genetic Epidemiology Research Institute and Department of Epidemiology, University of California at Irvine, Irvine, California

  2. 2

    Division of Hematology/Oncology, Chao Family Comprehensive Cancer Center, University of California at Irvine Medical Center, Orange, California

  3. 3

    Division of Cancer Etiology, Department of Population Sciences, City of Hope National Medical Center, Duarte, California

  4. 4

    Division of Surveillance Research, Northern California Cancer Center, Fremont, California

  5. 5

    Department of Preventive Medicine, Keck School of Medicine, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California

  1. ‡

    Fax: (949) 824-1343

*Department of Epidemiology, School of Medicine, University of California, Irvine, 224 Irvine Hall, Irvine, CA 92697-7550

  1. †

    Presented in part at the American Society of Preventive Oncology Annual Meeting, Bethesda, Maryland, March 16–18, 2008.

Publication History

  1. Issue published online: 2 DEC 2009
  2. Article first published online: 13 OCT 2009
  3. Manuscript Accepted: 20 APR 2009
  4. Manuscript Revised: 14 APR 2009
  5. Manuscript Received: 4 FEB 2009

Funded by

  • National Cancer Institute. Grant Numbers: R01 CA77398, R25 CA85771
  • National Institute of Environmental Health Sciences. Grant Number: P30 ES 07,048
  • California Breast Cancer Research Fund. Grant Number: 97-10,500

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (146K)

References

  • 1
    Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin. 2007; 57: 43-66.
    Direct Link:
  • 2
    Reddy BS, Maruyama H, Kelloff G. Dose-related inhibition of colon carcinogenesis by dietary piroxicam, a nonsteroidal antiinflammatory drug, during different stages of rat colon tumor development. Cancer Res. 1987; 47: 5340-5346.
  • 3
    Boolbol SK, Dannenberg AJ, Chadburn A, et al. Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res. 1996; 56: 2556-2560.
  • 4
    Barnes CJ, Lee M. Chemoprevention of spontaneous intestinal adenomas in the adenomatous polyposis coli Min mouse model with aspirin. Gastroenterology. 1998; 114: 873-877.
  • 5
    Jacoby RF, Seibert K, Cole CE, Kelloff G, Lubet RA. The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis. Cancer Res. 2000; 60: 5040-5044.
  • 6
    Reddy BS. Studies with the azoxymethane-rat preclinical model for assessing colon tumor development and chemoprevention. Environ Mol Mutagen. 2004; 44: 26-35.
    Direct Link:
  • 7
    Hu Y, Le Leu RK, Young GP. Sulindac corrects defective apoptosis and suppresses azoxymethane-induced colonic oncogenesis in p53 knockout mice. Int J Cancer. 2005; 116: 870-875.
    Direct Link:
  • 8
    Zell JA, Ignatenko NA, Yerushalmi HF, et al. Risk and risk reduction involving arginine intake and meat consumption in colorectal tumorigenesis and survival. Int J Cancer. 2007; 120: 459-468.
    Direct Link:
  • 9
    Labayle D, Fischer D, Vielh P, et al. Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology. 1991; 101: 635-639.
  • 10
    Giardiello FM, Hamilton SR, Krush AJ, et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med. 1993; 328: 1313-1316.
  • 11
    Nugent KP, Farmer KCR, Spigelman AD, Williams CB, Phillips RKS. Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell-proliferation in patients with familial adenomatous polyposis. Br J Surg. 1993; 80: 1618-1619.
    Direct Link:
  • 12
    Steinbach G, Lynch PM, Phillips RKS, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med. 2000; 342: 1946-1952.
  • 13
    Higuchi T, Iwama T, Yoshinaga K, Toyooka M, Taketo MM, Sugihara K. A randomized, double-blind, placebo-controlled trial of the effects of rofecoxib, a selective cyclooxygenase-2 inhibitor, on rectal polyps in familial adenomatous polyposis patients. Clin Cancer Res. 2003; 9: 4756-4760.
  • 14
    Baron JA, Cole BF, Sandler RS, et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med. 2003; 348: 891-899.
  • 15
    Sandler RS, Halabi S, Baron JA, et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med. 2003; 348: 883-890.
  • 16
    Asano TK, McLeod RS. Nonsteroidal anti-inflammatory drugs and aspirin for the prevention of colorectal adenomas and cancer: a systematic review. Dis Colon Rectum. 2004; 47: 665-673.
  • 17
    Chan AT, Giovannucci EL, Schernhammer ES, et al. A prospective study of aspirin use and the risk for colorectal adenoma. Ann Intern Med. 2004; 140: 157-166.
  • 18
    Poynter JN, Gruber SB, Higgins PD, et al. Statins and the risk of colorectal cancer. N Engl J Med. 2005; 352: 2184-2192.
  • 19
    Raju R, Cruz-Correa M. Chemoprevention of colorectal cancer. Dis Colon Rectum. 2006; 49: 113-124.
  • 20
    Chan AT, Giovannucci EL, Meyerhardt JA, Schernhammer ES, Curhan GC, Fuchs CS. Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer. JAMA. 2005; 294: 914-923.
  • 21
    Mahipal A, Anderson KE, Limburg PJ, Folsom AR. Nonsteroidal anti-inflammatory drugs and subsite-specific colorectal cancer incidence in the Iowa Women's Health Study. Cancer Epidemiol Biomarkers Prev. 2006; 15: 1785-1790.
  • 22
    Shaheen NJ, Straus WL, Sandler RS. Chemoprevention of gastrointestinal malignancies with nonsteroidal anti inflammatory drugs: a review. Cancer. 2002; 94: 950-963.
    Direct Link:
  • 23
    Jacobs EJ, Thun MJ, Bain EB, Rodriguez C, Henley SJ, Calle EE. A large cohort study of long-term daily use of adult-strength aspirin and cancer incidence. J Natl Cancer Inst. 2007; 99: 608-615.
  • 24
    Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Ascherio A, Willett WC. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann Intern Med. 1994; 121: 241-246.
  • 25
    Fuchs C, Meyerhardt JA, Heseltine DL, et al. Influence of regular aspirin use on survival for patients with stage III colon cancer: findings from Intergroup trial CALGB 89803. J Clin Oncol. 2005; 23( 16 suppl pt I): 3530.
  • 26
    Bernstein L, Allen M, Anton-Culver H, et al. High breast cancer incidence rates among California teachers: results from the California Teachers Study (United States). Cancer Causes Control. 2002; 13: 625-635.
  • 27
    Kwong S, Perkin C, Morris C, Cohen R, Allen M, Wright W. Cancer in California: 1988-1999. Sacramento, CA: California Department of Health Services, Cancer Surveillance Section; 2001.
  • 28
    Fritz A, Percy C, Jack A, Shanmugaratnam K, Parkin DM, Whelan S. International Classification of Diseases for Oncology. 3rd ed. Geneva, Switzerland: World Health Organization; 2000.
  • 29
    Horn-Ross PL, Hoggatt KJ, West DW, et al. Recent diet and breast cancer risk: the California Teachers Study (USA). Cancer Causes Control. 2002; 13: 407-415.
  • 30
    Young J, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA. SEER Summary Staging Manual—2000: Codes and Coding Instructions. Bethesda, Md: National Cancer Institute; 2001.
  • 31
    Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology. 1994; 107: 1183-1188.
  • 32
    Sheng H, Shao J, Kirkland SC, et al. Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J Clin Invest. 1997; 99: 2254-2259.
  • 33
    Chan AT, Ogino S, Fuchs CS. Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med. 2007; 356: 2131-2142.
  • 34
    Blanke CD, Mattek NC, Deloughery TG, Koop DR. A phase I study of 5-fluorouracil, leucovorin, and celecoxib in patients with incurable colorectal cancer. Prostaglandins Other Lipid Mediat. 2005; 75: 169-172.
  • 35
    Brown JR, DuBois RN. COX-2: a molecular target for colorectal cancer prevention. J Clin Oncol. 2005; 23: 2840-2855.
  • 36
    Blanke CD. Celecoxib with chemotherapy in colorectal cancer. Oncology (Williston Park). 2002; 16( 4 suppl 3): 17-21.
  • 37
    Dannenberg AJ, Altorki NK, Boyle JO, et al. Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer. Lancet Oncol. 2001; 2: 544-551.
  • 38
    Bertagnolli MM, Eagle CJ, Zauber AG, et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med. 2006; 355: 873-884.
  • 39
    Solomon SD, Pfeffer MA, McMurray JJV, et al. Effect of celecoxib on cardiovascular events and blood pressure in 2 trials for the prevention of colorectal adenomas. Circulation. 2006; 114: 1028-1035.
  • 40
    Rostom A, Dube C, Lewin G, et al. Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force. Ann Intern Med. 2007; 146: 376-389.
  • 41
    Fuchs CS, Giovannucci EL, Colditz GA, Hunter DJ, Speizer FE, Willett WC. A prospective study of family history and the risk of colorectal cancer. N Engl J Med. 1994; 331: 1669-1674.
  • 42
    Johns LE, Houlston RS. A systematic review and meta-analysis of familial colorectal cancer risk. Am J Gastroenterol. 2001; 96: 2992-3003.
    Direct Link:
  • 43
    Potter JD, Slattery ML, Bostick RM, Gapstur SM. Colon cancer: a review of the epidemiology. Epidemiol Rev. 1993; 15: 499-545.
  • 44
    Slattery ML, Kerber RA. Family history of cancer and colon cancer risk: the Utah Population Database. J Natl Cancer Inst. 1994; 86: 1618-1626.
  • 45
    Kune GA, Kune S, Watson LF. The effect of family history of cancer, religion, parity and migrant status on survival in colorectal cancer. Eur J Cancer. 1992; 28: 1484-1487.
  • 46
    Slattery ML, Kerber RA. The impact of family history of colon cancer on survival after diagnosis with colon cancer. Int J Epidemiol. 1995; 24: 888-896.
  • 47
    Bass AJ, Meyerhardt JA, Chan JA, Giovannucci EL, Fuchs CS. Family history and survival after colorectal cancer diagnosis. Cancer. 2008; 112: 1222-1229.
    Direct Link:
  • 48
    Registry Committee, Japanese Research Society for Cancer of the Colon and Rectum. Clinical and pathological analyses of patients with a family history of colorectal cancer. Jpn J Clin Oncol. 1993; 23: 342-349.
  • 49
    Chan JA, Meyerhardt JA, Niedzwiecki D, et al. Association of family history with cancer recurrence and survival among patients with stage III colon cancer. JAMA. 2008; 299: 2515-2523.
  • 50
    Zell JA, Honda J, Ziogas A, Anton-Culver H. Survival after colorectal cancer diagnosis is associated with colorectal cancer family history. Cancer Epidemiol Biomarkers Prev. 2008; 17: 3134-3140.
View Full Article (HTML) Get PDF (146K)